|
Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors. |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Patents, Royalties, Other Intellectual Property - Abjenix; Berlex; MedImmune |
Travel, Accommodations, Expenses - MedImmune |
|
|
|
Stock and Other Ownership Interests - MedImmune |
Research Funding - MedImmune |
Patents, Royalties, Other Intellectual Property - MedImmune |
Travel, Accommodations, Expenses - MedImmune |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Patents, Royalties, Other Intellectual Property - MedImmune |
|
|
Employment - MedImmune; MedImmune (I) |
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I); GlaxoSmithKline; GlaxoSmithKline (I) |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
|
|
|
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
|
|
|
Stock and Other Ownership Interests - MedImmune |
Patents, Royalties, Other Intellectual Property - MedImmune (Inst) |
Travel, Accommodations, Expenses - MedImmune |
|
|
Employment - MedImmune; MedImmune (I) |
Stock and Other Ownership Interests - MedImmune; MedImmune (I) |